Biotechnology
Healthcare
Investing News
Market News
Technology
The Market Buzz
Longeveron’s Lomecel-B Approved by FDA for Rare Pediatric Disease Designation
Longeveron Inc. (NASDAQ: LGVN) has received approval for Rare Pediatric Disease Designation for Lomecel-B by the FDA to treat Hypoplastic Left Heart Syndrom. HLHS is a rare life-threatening congenital...